Abstract: Provided is a biomarker for detecting cancer, in particular prostate cancer in a male subject, the biomarker comprising at least one homeodomain containing transcription factor, such as a HOX peptide or EN-2 peptide, or a fragment thereof. The use of said biomarker in detecting and/or treating prostate cancer is provided, together with methods and kits therefor.

Abstract: The present invention relates to peptides which impair PBX-dependent regulation of gene transcription. In particular, the invention provides the use of a peptide comprising the amino acid sequence X1 X2 X3 W M X4 X5 X6 X7, wherein the sequence X1 to X7 is an amino acid sequence comprising at least 9 amino acids, which may optionally be interrupted by one or two amino acid residues between one or more of the 9 amino acid positions defined herein; X1 is selected from W, T, PE, KQI, VV, PQT, H, RI and absent; X2 is an amino acid with an aromatic side chain; X3 is P or D; X4 is an amino acid with a basic side chain; X5 is an amino acid with a charged side chain; X6 is an amino acid with a charged side chain; and X7 is an amino acid with a basic side chain or Serine; in the manufacture of a medicament for treating or preventing a disorder in which aberrant cell division occurs.

Abstract: Provided is a biomarker for detecting cancer, in particular prostate cancer in a male subject, the biomarker comprising at least one homeodomain containing transcription factor, such as a HOX peptide or EN-2 peptide, or a fragment thereof. The use of said biomarker in detecting and/or treating prostate cancer is provided, together with methods and kits therefor.

Abstract: The present invention relates to peptides, which impair PBX-dependent regulation of gene transcription and thus have utility in the treatment or prevention of disorders in which aberrant cell division occurs.